Who Paid My Doc
Kamel El Salek
Vascular & Interventional Radiology Las Vegas, NV Medical Doctor
NPI 1457884579 CMS profile 11566373
2020 Palomino Ln Ste 100, Las Vegas, NV 89106
General payments
$12,316
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Kamel El Salek of Las Vegas, NV is reported in the CMS Open Payments database as having received $12,316 across 121 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 80th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $3,685 | 47 | |
| 2024 | General | $8,542 | 73 | |
| 2023 | General | $89 | 1 |
Beside peers
- Kamel El Salek
- Vascular & Interventional Radiology median
- Middle half of Vascular & Interventional Radiology
- National median
In program year 2025, general payments to Kamel El Salek were reported at $3,685. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.
Show as a table
| Year | Kamel El Salek | Vascular & Interventional Radiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $422 | $125–$1,555 | $163 |
| 2020 | $0 | $200 | $68–$652 | $114 |
| 2021 | $0 | $280 | $99–$866 | $132 |
| 2022 | $0 | $433 | $137–$1,497 | $149 |
| 2023 | $89 | $506 | $152–$2,019 | $160 |
| 2024 | $8,542 | $556 | $175–$1,930 | $164 |
| 2025 | $3,685 | $534 | $166–$2,075 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 159 billing codesPaid by Medicare
$75,783
Medicare patients
889
Services billed
3,325
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 57% | |
| Diabetes | 49% | |
| Ischemic heart disease | 46% | |
| Chronic kidney disease | 46% | |
| Heart failure | 38% | |
| COPD | 38% | |
| Depression | 33% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 | Office | 18 | 1,985 | $206 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
121 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Vascular & Interventional Radiology in Nevada
Practitioners in the same specialty and state, ranked by reported value.
All Vascular & Interventional Radiology
Everyone recorded under this specialty, nationwide.
Doctors in Nevada
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.